anastrozole has been researched along with Cancer of Liver in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 9.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 9.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 8.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 7.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 5.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 5.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 4.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 3.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "MRI study revealed brain metastases with a diameter of 1 cm in her right midbrain in April 2005, so a gamma knife radio-surgery was performed." | 1.33 | [Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weiner, A | 1 |
| D'Andrea, GM | 1 |
| Mathew, J | 1 |
| Prinsloo, P | 1 |
| Agrawal, A | 1 |
| Gutteridge, E | 1 |
| Marenah, C | 1 |
| Robertson, JF | 2 |
| Cheung, KL | 1 |
| Campos, SM | 1 |
| Guastalla, JP | 1 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Winer, EP | 1 |
| Cameron, DA | 1 |
| Ichinose, Y | 1 |
| Kobayashi, T | 1 |
| Fujimoto, A | 1 |
| Uchida, S | 1 |
| Sasaoki, T | 1 |
| Goto, K | 1 |
| Mauriac, L | 1 |
| Pippen, JE | 1 |
| Quaresma Albano, J | 1 |
| Gertler, SZ | 1 |
| Osborne, CK | 1 |
| Howell, A | 1 |
| Vergote, I | 1 |
| Hojo, S | 1 |
| Maeura, Y | 1 |
| Yoshioka, S | 1 |
| Fujie, Y | 1 |
| Fukunaga, H | 1 |
| Okada, Y | 1 |
| Ota, H | 1 |
| Endo, W | 1 |
| Matsumoto, C | 1 |
| Ishikawa, T | 1 |
| Momiyama, N | 1 |
| Chishima, T | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Inui, K | 1 |
| Shimada, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for anastrozole and Cancer of Liver
| Article | Year |
|---|---|
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
3 trials available for anastrozole and Cancer of Liver
| Article | Year |
|---|---|
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neo | 2014 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Fema | 2003 |
4 other studies available for anastrozole and Cancer of Liver
| Article | Year |
|---|---|
Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Liver Neoplas | 2018 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2006 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationshi | 2007 |